We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?
Read MoreHide Full Article
Key Takeaways
ISRG's third-quarter 2026 revenues rose 22% to just over $3 billion, outpacing 15% procedure growth.
Da Vinci placements jumped 28% to 546 systems, while recurring revenues accounted for 84% of total sales.
Planned pricing changes could cut I&A revenue per procedure by 3-5%, offset by innovation and product mix.
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2026 revenues increased 22% year over year to just over $3 billion, outpacing 15% growth in total da Vinci and Ion procedures. Sales growth substantially exceeding procedure growth underscores the company’s ability to capitalize on its expanding installed base, increased system placements and growing adoption of newer technologies. Recurring revenues accounted for 84% of total sales, highlighting the importance of instruments and accessories (I&A), system servicing and the broader installed-base ecosystem to revenue generation.
System placements were a major sales driver during the third quarter. Da Vinci placements increased 28% to 546 systems. Net da Vinci placements rose 40%, expanding the installed base significantly. Systems revenues grew 30% to $769 million, and service revenues increased 22% to $482 million.
Meanwhile, I&A revenues advanced 18% to $1.8 billion. The richer mix of da Vinci 5, single-port (SP) systems and Ion, along with higher integration and upgrade volumes, supported revenue growth beyond underlying procedure expansion. Higher SP utilization and da Vinci 5-specific instruments also lifted I&A revenue per procedure to approximately $1,860 from $1,800 a year earlier.
However, sustaining this gap may become more challenging as pricing initiatives take effect. Intuitive Surgical expects planned instrument pricing changes and China’s policy-driven price reductions to lower da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis, once fully implemented. The impact will build progressively through 2027.
Higher SP penetration, da Vinci 5 adoption, Force Feedback instruments and additional technology could partially offset the pressure. Management also expects cost-reduction programs to help absorb the modest gross-margin impact. Revenue growth may continue to outpace procedure growth, supported by expanding system placements, a favorable product mix and innovation-driven monetization despite pricing pressures.
Peer Updates
Boston Scientific’s (BSX - Free Report) third-quarter 2026 organic sales grew 1.5% year over year to $5.14 billion, with growth constrained by a cybersecurity incident that reduced sales growth by approximately 300 basis points, as per management estimates. Growth was supported by Neuromodulation (up 13%), including strong demand for Nalu peripheral nerve stimulation technology.
Interventional Cardiology sales increased 19%, driven by imaging and drug-eluting technologies. AGENT drug-coated balloons also continued gaining traction. However, EP sales fell 5% amid competition, while WATCHMAN declined 6%. Although sales are likely to continue its growth at current pace, cyber-related order normalization, EP competition and China pricing pressure could weigh on the metric.
GE HealthCare Technologies’ (GEHC - Free Report) third-quarter 2026 revenues increased 6.2% organically to approximately $5.5 billion, with growth across all segments. Product revenues rose 6.7%, while service revenues grew 8.1%, demonstrating strength in both equipment and services. Advanced Imaging Solutions benefited from CT, cardiovascular interventional solutions and surgical innovations, while Pharmaceutical Diagnostics grew 13.8% on demand for contrast media and radiopharmaceuticals.
New products, including AI-enabled imaging platforms and Flyrcado, supported demand, along with contributions from strategic pricing and premium product positioning. Strong demand across all segments is expected to support sales growth going forward. However, rising memory-chip prices, higher oil costs and pricing pressures could weigh on growth and profitability.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 21.6% so far this year compared with a 0.9% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.53, above the industry average. But, it is significantly lower than its five-year median of 66.94. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG Sales Jump 22%: Can Growth Stay Ahead of Procedure Volumes?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) third-quarter 2026 revenues increased 22% year over year to just over $3 billion, outpacing 15% growth in total da Vinci and Ion procedures. Sales growth substantially exceeding procedure growth underscores the company’s ability to capitalize on its expanding installed base, increased system placements and growing adoption of newer technologies. Recurring revenues accounted for 84% of total sales, highlighting the importance of instruments and accessories (I&A), system servicing and the broader installed-base ecosystem to revenue generation.
System placements were a major sales driver during the third quarter. Da Vinci placements increased 28% to 546 systems. Net da Vinci placements rose 40%, expanding the installed base significantly. Systems revenues grew 30% to $769 million, and service revenues increased 22% to $482 million.
Meanwhile, I&A revenues advanced 18% to $1.8 billion. The richer mix of da Vinci 5, single-port (SP) systems and Ion, along with higher integration and upgrade volumes, supported revenue growth beyond underlying procedure expansion. Higher SP utilization and da Vinci 5-specific instruments also lifted I&A revenue per procedure to approximately $1,860 from $1,800 a year earlier.
However, sustaining this gap may become more challenging as pricing initiatives take effect. Intuitive Surgical expects planned instrument pricing changes and China’s policy-driven price reductions to lower da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis, once fully implemented. The impact will build progressively through 2027.
Higher SP penetration, da Vinci 5 adoption, Force Feedback instruments and additional technology could partially offset the pressure. Management also expects cost-reduction programs to help absorb the modest gross-margin impact. Revenue growth may continue to outpace procedure growth, supported by expanding system placements, a favorable product mix and innovation-driven monetization despite pricing pressures.
Peer Updates
Boston Scientific’s (BSX - Free Report) third-quarter 2026 organic sales grew 1.5% year over year to $5.14 billion, with growth constrained by a cybersecurity incident that reduced sales growth by approximately 300 basis points, as per management estimates. Growth was supported by Neuromodulation (up 13%), including strong demand for Nalu peripheral nerve stimulation technology.
Interventional Cardiology sales increased 19%, driven by imaging and drug-eluting technologies. AGENT drug-coated balloons also continued gaining traction. However, EP sales fell 5% amid competition, while WATCHMAN declined 6%. Although sales are likely to continue its growth at current pace, cyber-related order normalization, EP competition and China pricing pressure could weigh on the metric.
GE HealthCare Technologies’ (GEHC - Free Report) third-quarter 2026 revenues increased 6.2% organically to approximately $5.5 billion, with growth across all segments. Product revenues rose 6.7%, while service revenues grew 8.1%, demonstrating strength in both equipment and services. Advanced Imaging Solutions benefited from CT, cardiovascular interventional solutions and surgical innovations, while Pharmaceutical Diagnostics grew 13.8% on demand for contrast media and radiopharmaceuticals.
New products, including AI-enabled imaging platforms and Flyrcado, supported demand, along with contributions from strategic pricing and premium product positioning. Strong demand across all segments is expected to support sales growth going forward. However, rising memory-chip prices, higher oil costs and pricing pressures could weigh on growth and profitability.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 21.6% so far this year compared with a 0.9% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 36.53, above the industry average. But, it is significantly lower than its five-year median of 66.94. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 25.9% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.